S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
Log in
NYSE:RMD

ResMed Stock Forecast, Price & News

$217.96
+3.06 (+1.42 %)
(As of 01/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$213.76
Now: $217.96
$218.86
50-Day Range
$204.53
MA: $212.48
$220.30
52-Week Range
$108.85
Now: $217.96
$224.24
Volume444,737 shs
Average Volume455,189 shs
Market Capitalization$31.59 billion
P/E Ratio46.77
Dividend Yield0.73%
Beta0.28
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
ResMed logo

MarketRank

Overall MarketRank

1.38 out of 5 stars

Medical Sector

576th out of 1,928 stocks

Surgical & Medical Instruments Industry

60th out of 170 stocks

Analyst Opinion: 1.2Community Rank: 1.8Dividend Strength: 1.7Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP76115210
Phone858-836-5000
Employees7,770

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.96 billion
Cash Flow$6.08 per share
Book Value$17.26 per share

Profitability

Net Income$621.67 million

Miscellaneous

Market Cap$31.59 billion
Next Earnings Date1/28/2021 (Confirmed)
OptionableOptionable
$217.96
+3.06 (+1.42 %)
(As of 01/20/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RMD News and Ratings via Email

Sign-up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ResMed (NYSE:RMD) Frequently Asked Questions

How has ResMed's stock price been impacted by Coronavirus?

ResMed's stock was trading at $153.61 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, RMD stock has increased by 41.9% and is now trading at $217.96.
View which stocks have been most impacted by COVID-19
.

Is ResMed a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ResMed stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RMD, but not buy additional shares or sell existing shares.
View analyst ratings for ResMed
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than ResMed?

Wall Street analysts have given ResMed a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ResMed wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Thomas Greco's approval rating as ResMed's CEO?

538 employees have rated ResMed CEO Thomas Greco on Glassdoor.com. Thomas Greco has an approval rating of 63% among ResMed's employees. This puts Thomas Greco in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is ResMed's next earnings date?

ResMed is scheduled to release its next quarterly earnings announcement on Thursday, January 28th 2021.
View our earnings forecast for ResMed
.

How can I listen to ResMed's earnings call?

ResMed will be holding an earnings conference call on Thursday, January 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) released its earnings results on Thursday, October, 29th. The medical equipment provider reported $1.27 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.98 by $0.29. The medical equipment provider earned $751.90 million during the quarter, compared to analysts' expectations of $709.47 million. ResMed had a return on equity of 30.64% and a net margin of 22.45%. ResMed's quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.93 earnings per share.
View ResMed's earnings history
.

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed announced a quarterly dividend on Thursday, October 29th. Stockholders of record on Thursday, November 12th will be given a dividend of $0.39 per share on Thursday, December 17th. This represents a $1.56 annualized dividend and a yield of 0.72%. The ex-dividend date of this dividend is Tuesday, November 10th.
View ResMed's dividend history
.

Is ResMed a good dividend stock?

ResMed pays an annual dividend of $1.56 per share and currently has a dividend yield of 0.73%. The dividend payout ratio of ResMed is 32.77%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ResMed will have a dividend payout ratio of 28.26% next year. This indicates that ResMed will be able to sustain or increase its dividend.
View ResMed's dividend history.

What price target have analysts set for RMD?

10 analysts have issued 12 month target prices for ResMed's shares. Their forecasts range from $165.00 to $210.00. On average, they expect ResMed's share price to reach $189.40 in the next twelve months. This suggests that the stock has a possible downside of 13.1%.
View analysts' price targets for ResMed
or view Wall Street analyst' top-rated stocks.

Who are some of ResMed's key competitors?

What other stocks do shareholders of ResMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include NVIDIA (NVDA), The Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Adobe (ADBE), Visa (V), Alibaba Group (BABA), PayPal (PYPL) and QUALCOMM (QCOM).

Who are ResMed's key executives?

ResMed's management team includes the following people:
  • Dr. Peter C. Farrell A.M., B.E., Ph.D., BE (Hons), ScD, AM, Founder & Non-Exec. Chairman (Age 78, Pay $431.8k)
  • Mr. Michael J. Farrell BE, SM, MBA, CEO & Director (Age 48, Pay $2.73M)
  • Mr. Robert A. Douglas, Pres & COO (Age 60, Pay $1.99M)
  • Mr. Brett A. Sandercock, Chief Financial Officer (Age 53, Pay $907.65k)
  • Dr. James R. Hollingshead Ph.D., Pres of Sleep & Respiratory Care Bus. (Age 57, Pay $1.27M)
  • Mr. Rajwant Singh Sodhi, Pres of Software as a Service Bus. (SaaS) (Age 47, Pay $1.04M)
  • Mr. Kaushik Ghoshal, Chief Technology Officer
  • Mr. David B. Pendarvis, Chief Admin. Officer, Global Gen. Counsel & Sec. (Age 61)
  • Ms. Constance C. Bienfait, Director of Investor Relations
  • Ms. Amy Wakeham, VP of Investor Relations & Corp. Communications

What is ResMed's stock symbol?

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

Who are ResMed's major shareholders?

ResMed's stock is owned by many different retail and institutional investors. Top institutional investors include Welch & Forbes LLC (0.21%), Frontier Capital Management Co. LLC (0.16%), Ardevora Asset Management LLP (0.15%), Capital Investment Services of America Inc. (0.10%), Tandem Investment Advisors Inc. (0.06%) and State of Alaska Department of Revenue (0.05%). Company insiders that own ResMed stock include Brett Sandercock, David Pendarvis, James Hollingshead, John P Wareham, Justin Leong, Michael J Farrell, Rajwant Sodhi, Richard Mchale, Robert Andrew Douglas and Ronald R Taylor.
View institutional ownership trends for ResMed
.

Which institutional investors are selling ResMed stock?

RMD stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Ardevora Asset Management LLP, State of Alaska Department of Revenue, Hudson Valley Investment Advisors Inc. ADV, Pacer Advisors Inc., Welch & Forbes LLC, Campbell Capital Management Inc., and Diversified Trust Co. Company insiders that have sold ResMed company stock in the last year include Brett Sandercock, David Pendarvis, James Hollingshead, Justin Leong, Michael J Farrell, Rajwant Sodhi, and Robert Andrew Douglas.
View insider buying and selling activity for ResMed
or view top insider-selling stocks.

Which institutional investors are buying ResMed stock?

RMD stock was purchased by a variety of institutional investors in the last quarter, including Tandem Investment Advisors Inc., Crossmark Global Holdings Inc., Capital Investment Services of America Inc., Kestra Advisory Services LLC, IFM Investors Pty Ltd, Breiter Capital Management Inc., MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH, and Louisiana State Employees Retirement System.
View insider buying and selling activity for ResMed
or or view top insider-buying stocks.

How do I buy shares of ResMed?

Shares of RMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ResMed's stock price today?

One share of RMD stock can currently be purchased for approximately $217.96.

How big of a company is ResMed?

ResMed has a market capitalization of $31.59 billion and generates $2.96 billion in revenue each year. The medical equipment provider earns $621.67 million in net income (profit) each year or $4.76 on an earnings per share basis. ResMed employs 7,770 workers across the globe.

What is ResMed's official website?

The official website for ResMed is www.resmed.com.

How can I contact ResMed?

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The medical equipment provider can be reached via phone at 858-836-5000 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.